CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D012891: Sleep Apnea Syndromes NIH

(Synonyms: Sleep A, Sleep Ap, Sleep Apn, Sleep Apne, Sleep Apnea Sy, Sleep Apnea Syn, Sleep Apnea Synd, Sleep Apnea Syndr, Sleep Apnea Syndrom, Sleep Apnea Syndrome, Sleep Apnea Syndromes, Sleep Apnea,, Sleep Apnea,)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug638 Polysomnography Wiki 1.00
drug132 Blood sample Wiki 0.58

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D020181 Sleep Apnea, Obstructive NIH 1.00
D001049 Apnea NIH 1.00
D011014 Pneumonia NIH 0.08

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Impact of Obstructive Sleep Apnea on Covid-19 Outcomes (OSACOVID-19 Study): A Prospective Observational Cohort Study

Covid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.

NCT04363333 COVID Obstructive Sleep Apnea Pneumonia Diagnostic Test: Polysomnography
MeSH:Apnea Sleep Apnea Syndromes Pneumonia Sleep Apnea, Obstructive
HPO:Apnea Obstructive sleep apnea Pneumonia Sleep apnea

Primary Outcomes

Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale

Measure: The rate of clinical improvement

Time: 28 days

Secondary Outcomes

Description: Time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality

Measure: Clinical status

Time: 7, 14, 21, 28 days

Other Outcomes

Description: Re-analysis of the correlation of obstructive sleep apnea (objectively verified) severity in terms of apnea-hypopnea index and oxygenation levels with the primary and secondary outcomes as described above (the rate of clinical improvement defined as a decline of 2 categories from admission on a 7-category ordinal scale; time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality as well as with the lung function, CO-diffusion capacity, cardiac function, CT thorax pathologies, biomarkers (cytokines, polymorphisms) and IgG-antibodies after 4 months.

Measure: Long-term outcomes

Time: 4 months after the initial hospital admission


HPO Nodes